Waning Vaccine Immunity and Vaccination Responses in Children Treated for Acute Lymphoblastic Leukemia: A Canadian Immunization Research Network Study.
chemotherapy
immunization
immunosuppression
vaccination
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
03 12 2020
03 12 2020
Historique:
received:
31
10
2019
accepted:
13
02
2020
pubmed:
19
2
2020
medline:
28
4
2021
entrez:
19
2
2020
Statut:
ppublish
Résumé
There is no uniform guideline for postchemotherapy vaccination of children with acute lymphoblastic leukemia (ALL). We evaluated waning immunity to 14 pneumococcal serotypes, pertussis toxin (PT), tetanus toxoid (TT) and varicella, and immunogenicity of postchemotherapy diphtheria, tetanus, pertussis, hepatitis B, polio, and Haemophilus influenzae type b (DTaP-IPV-Hib) and pneumococcal vaccination among previously vaccinated children treated for ALL. This was a multicenter trial of children with ALL enrolled 4-12 months postchemotherapy completion. Exclusion criteria included: infant ALL, relapsed ALL, and stem cell transplant recipients. Immunocompetent children were recruited as controls. Postchemotherapy participants received DTaP-IPV-Hib and 13-valent pneumococcal conjugate vaccine (PCV13) concurrently, followed by 23-valent pneumococcal polysaccharide vaccine (PPV23) 2 months later. Serology was measured at baseline, 2 and 12 months postvaccination. Adverse events were captured via surveys. At enrollment, postchemotherapy participants (n = 74) were less likely than controls (n = 78) to be age-appropriately immunized with DTaP (41% vs 89%, P < .001) and PCV (59% vs 79%, P = .008). Geometric mean concentrations (GMCs) to TT, PT, PCV serotypes, and varicella were lower in postchemotherapy participants than controls after adjusting for previous vaccine doses (P < .001). Two months postvaccination, GMCs to TT, PT, and PCV serotypes increased from baseline (P < .001 for all antigens) and remained elevated at 12 months postvaccination. Antibody levels to PPV23 serotypes also increased postvaccination (P < .001). No serious adverse events were reported. Children treated for ALL had lower antibody levels than controls against pneumococcal serotypes, tetanus, pertussis, and varicella despite previous vaccination. Postchemotherapy vaccination with DTaP-IPV-Hib, PCV13, and PPV23 was immunogenic and well tolerated. Children with ALL would benefit from systematic revaccination postchemotherapy. NCT02447718.
Sections du résumé
BACKGROUND
There is no uniform guideline for postchemotherapy vaccination of children with acute lymphoblastic leukemia (ALL). We evaluated waning immunity to 14 pneumococcal serotypes, pertussis toxin (PT), tetanus toxoid (TT) and varicella, and immunogenicity of postchemotherapy diphtheria, tetanus, pertussis, hepatitis B, polio, and Haemophilus influenzae type b (DTaP-IPV-Hib) and pneumococcal vaccination among previously vaccinated children treated for ALL.
METHODS
This was a multicenter trial of children with ALL enrolled 4-12 months postchemotherapy completion. Exclusion criteria included: infant ALL, relapsed ALL, and stem cell transplant recipients. Immunocompetent children were recruited as controls. Postchemotherapy participants received DTaP-IPV-Hib and 13-valent pneumococcal conjugate vaccine (PCV13) concurrently, followed by 23-valent pneumococcal polysaccharide vaccine (PPV23) 2 months later. Serology was measured at baseline, 2 and 12 months postvaccination. Adverse events were captured via surveys.
RESULTS
At enrollment, postchemotherapy participants (n = 74) were less likely than controls (n = 78) to be age-appropriately immunized with DTaP (41% vs 89%, P < .001) and PCV (59% vs 79%, P = .008). Geometric mean concentrations (GMCs) to TT, PT, PCV serotypes, and varicella were lower in postchemotherapy participants than controls after adjusting for previous vaccine doses (P < .001). Two months postvaccination, GMCs to TT, PT, and PCV serotypes increased from baseline (P < .001 for all antigens) and remained elevated at 12 months postvaccination. Antibody levels to PPV23 serotypes also increased postvaccination (P < .001). No serious adverse events were reported.
CONCLUSIONS
Children treated for ALL had lower antibody levels than controls against pneumococcal serotypes, tetanus, pertussis, and varicella despite previous vaccination. Postchemotherapy vaccination with DTaP-IPV-Hib, PCV13, and PPV23 was immunogenic and well tolerated. Children with ALL would benefit from systematic revaccination postchemotherapy.
CLINICAL TRIALS REGISTRATION
NCT02447718.
Identifiants
pubmed: 32067048
pii: 5739670
doi: 10.1093/cid/ciaa163
pmc: PMC7713683
doi:
Substances chimiques
Antibodies, Bacterial
0
Diphtheria-Tetanus-Pertussis Vaccine
0
Haemophilus Vaccines
0
Hepatitis B Vaccines
0
Poliovirus Vaccine, Inactivated
0
Vaccines, Combined
0
Vaccines, Conjugate
0
Banques de données
ClinicalTrials.gov
['NCT02447718']
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e439-e448Subventions
Organisme : CIHR
ID : CNF-151944
Pays : Canada
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Blood. 2008 May 1;111(9):4477-89
pubmed: 18285545
Br J Haematol. 2009 Dec;147(5):700-5
pubmed: 19764991
Vaccine. 2004 Oct 22;22(31-32):4262-9
pubmed: 15474717
MMWR Morb Mortal Wkly Rep. 2013 Jun 28;62(25):521-4
pubmed: 23803961
Pediatr Infect Dis J. 2014 Feb;33(2):183-9
pubmed: 24136369
Hum Vaccin Immunother. 2016 Apr 2;12(4):931-6
pubmed: 26962702
J Pediatric Infect Dis Soc. 2017 Jun 1;6(2):e4-e6
pubmed: 28339568
J Pediatr. 2012 Dec;161(6):1091-6
pubmed: 22819634
Vaccine. 2014 Jun 5;32(27):3357-61
pubmed: 24793952
Clin Infect Dis. 2014 Feb;58(3):e44-100
pubmed: 24311479
Clin Infect Dis. 2016 Jan 15;62(2):139-47
pubmed: 26354970
Arch Dis Child. 2012 Jan;97(1):46-8
pubmed: 20705722
Pediatr Blood Cancer. 2017 Feb;64(2):315-320
pubmed: 27718310
Leukemia. 2006 Oct;20(10):1717-22
pubmed: 16888619
J Clin Microbiol. 2019 Jul 26;57(8):
pubmed: 31167847
J Pediatr Hematol Oncol. 2004 Nov;26(11):727-34
pubmed: 15543007
Pediatr Infect Dis J. 2017 Mar;36(3):319-325
pubmed: 27879555
Pediatrics. 1987 Oct;80(4):465-72
pubmed: 2821476
J Allergy Clin Immunol. 2003 Nov;112(5):973-80
pubmed: 14610491
Pediatrics. 2013 May;131(5):e1639-42
pubmed: 23589809
Clin Infect Dis. 2007 Mar 1;44(5):635-42
pubmed: 17278052
Pediatr Blood Cancer. 2012 May;58(5):701-7
pubmed: 21793184
Pediatr Infect Dis J. 1998 Aug;17(8):685-91
pubmed: 9726341
Pediatr Infect Dis J. 2018 Jul;37(7):726-728
pubmed: 29200182
Cancer. 2017 Nov 1;123(21):4215-4223
pubmed: 28696530
J Clin Oncol. 2019 Oct 10;37(29):2651-2660
pubmed: 31393747
Lancet Infect Dis. 2019 Jun;19(6):e188-e199
pubmed: 30744964
Vaccine. 2015 Aug 26;33(36):4579-85
pubmed: 26165918
J Clin Immunol. 2014 Apr;34(3):267-71
pubmed: 24596024
J Korean Med Sci. 2012 Jan;27(1):78-83
pubmed: 22219618
Br J Haematol. 2007 Jun;137(5):457-60
pubmed: 17488489
JAMA. 1992 Mar 4;267(9):1237-41
pubmed: 1538561
MMWR Morb Mortal Wkly Rep. 2014 Feb 21;63(7):161
pubmed: 24553201